关键词：乳腺癌；特征；导管癌；小叶癌；乳头癌
摘 要：Breast cancer is characterized by the uncontrolled growth of cancerous cells in the breast tissue. It occurs in both males and females; however, male breast cancer is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Ductal carcinoma is a condition where malignant cells are present in the lining of the milk ducts while in lobular carcinoma the cells are present in the milk glands of the breast. When breast cancer spreads from the site of origin to surrounding tissue, it is known as invasive breast cancer. Invasive ductal carcinoma is the most common subtype accounting for 70-80 percent of all the breast cancer cases. In women, breast cancer is the second most common form of cancer. GLOBOCAN reported that in 2012, breast cancer accounted for 11.9 percent of the total cancer cases and led to 522,000 deaths worldwide.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Treatment Regimen for Breast Cancer

08. Market Segmentation by Type of Therapy

08.1.1 Chemotherapy

08.1.2 Hormone Therapy

08.1.3 Targeted Therapy

09. Market Segmentation by Molecule Type

10. Monoclonal Antibodies Segment

11. Late-Stage Pipeline Portfolio

12. Geographical Segmentation

12.1 Breast Cancer Market in the Americas

12.1.1 Market Size and Forecast

12.2 Breast Cancer Market in the EMEA Region

12.2.1 Market Size and Forecast

12.3 Breast Cancer Market in the APAC Region

12.3.1 Market Size and Forecast

12.3.2 Country-wise Segmentation of the APAC region 2013

13. Buying Criteria

14. Market Growth Drivers

15. Drivers and their Impact

16. Market Challenges

17. Impact of Drivers and Challenges

18. Market Trends

19. Trends and their Impact

20. Vendor Landscape

20.1 Competitive Scenario

20.1.1 Key News

20.1.2 Mergers and Acquisitions

20.2 Market Share Analysis 2013

20.2.1 AstraZeneca plc

20.2.2 Eli Lilly & Co.

20.2.3 F. Hoffmann-La Roche Ltd.

20.2.4 Novartis AG

20.2.5 Sanofi SA

20.3 Other Prominent Vendors

21. Key Vendor Analysis

21.1 AstraZeneca plc

21.1.1 Key Facts

21.1.2 Business Overview

21.1.3 Business Segmentation

21.1.4 Business Strategy

21.1.5 Revenue by Business Segmentation

21.1.6 Revenue Comparison 2011-2013

21.1.7 Sales by Geography

21.1.8 Key Developments

21.1.9 SWOT Analysis

21.1.10 Strengths

21.1.11 Weaknesses 6

21.1.12 Opportunities

21.1.13 Threats

21.2 Eli Lilly & Co.

21.2.1 Key Facts

21.2.2 Business Overview

21.2.3 Business Segmentation

21.2.4 Business Segmentation Revenue by 2013

21.2.5 Revenue Comparison 2012 and 2013

21.2.6 Sales by Geography

21.2.7 Business Strategy

21.2.8 Key Developments

21.2.9 SWOT Analysis

21.2.10 Strengths

21.2.11 Weaknesses

21.2.12 Opportunities

21.2.13 Threats

21.3 F. Hoffmann-La Roche Ltd.

21.3.1 Key Facts

21.3.2 Business Overview

21.3.3 Business Segmentation

21.3.4 Business Strategy

21.3.5 Business Segmentation by Revenue 2013

21.3.6 Sales by Geography

21.3.7 Key Information

21.3.8 SWOT Analysis

21.3.9 Strengths

21.3.10 Weaknesses

21.3.11 Opportunities

21.3.12 Threats

21.4 Novartis AG

21.4.1 Key Facts

21.4.2 Business Overview

21.4.3 Business Segmentation

21.4.4 Revenue by Business Segmentation

21.4.5 Revenue Comparison 2012 and 2013

21.4.6 Sales by Geography

21.4.7 Business Strategy

21.4.8 Key Developments

21.4.9 SWOT Analysis

21.4.10 Strengths

21.4.11 Weaknesses

21.4.12 Opportunities

21.4.13 Threats

21.5 Sanofi SA

21.5.1 Key Facts

21.5.2 Business Overview

21.5.3 Business Segmentation

21.5.4 Revenue by Business Segmentation

21.5.5 Revenue Comparison 2012 and 2013

21.5.6 Sales by Geography

21.5.7 Business Strategy

21.5.8 Key Developments

21.5.9 SWOT Analysis

21.5.10 Strengths

21.5.11 Weaknesses

21.5.12 Opportunities

21.5.13 Threats

22. Other Reports in this Series